论文部分内容阅读
血液的凝固作用与抗凝作用保持动态平衡是机体防止出血及血栓形成的重要调节机制。在血浆的天然抗凝血物质如抗凝血酶Ⅲ(AT-Ⅲ)、α_1抗胰蛋白酶、αv2巨球蛋白、肝素等中,AT-Ⅲ是最主要的凝血酶抑制物,它占总抗凝血活性的50～70%。近十多年来,AT-Ⅲ的研究工作一直很活跃,对先天性及获得性AT-Ⅲ缺陷症的实验室诊断、发病率、治疗及预防的研究均取得了很大进展。现将若干进展情况作一简要综述。一、AT-Ⅲ的理化性状及生理功能 AT-Ⅲ是一种含糖10%的单链α_2糖蛋白,分子量约为67000,沉降系数4.46 s,等
Blood coagulation and anticoagulation to maintain the dynamic balance of the body to prevent bleeding and thrombosis is an important regulatory mechanism. AT-III is the most predominant thrombin inhibitor in the plasma of natural anticoagulant substances such as antithrombin III (AT-III), alpha 1 antitrypsin, alpha v2 macroglobulin, heparin and the like, 50 ~ 70% of coagulation activity. In the recent ten years, the research work of AT-III has been very active. Great progress has been made in the laboratory diagnosis, incidence, treatment and prevention of congenital and acquired AT-III deficiency. We will make a brief summary of some progress. First, AT-Ⅲ physical and chemical properties and physiological functions AT-Ⅲ is a sugar 10% single-chain α 2 glycoprotein, molecular weight of about 67000, sedimentation coefficient 4.46 s, etc.